$3.01
16.67% today
Nasdaq, Apr 02, 09:15 pm CET
ISIN
US1856341029
Symbol
CLNN
Sector
Industry

Clene Inc Stock price

$2.58
-1.75 40.42% 1M
-2.02 43.91% 6M
-2.73 51.41% YTD
-5.82 69.28% 1Y
-72.22 96.55% 3Y
-207.42 98.77% 5Y
-190.42 98.66% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.50 16.23%
ISIN
US1856341029
Symbol
CLNN
Sector
Industry

Key metrics

Market capitalization $22.15m
Enterprise Value $30.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 90.68
P/S ratio (TTM) P/S ratio 65.15
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -47.71%
Revenue (TTM) Revenue $340.00k
EBIT (operating result TTM) EBIT $-33.09m
Free Cash Flow (TTM) Free Cash Flow $-21.42m
Cash position $12.16m
EPS (TTM) EPS $-1.87
P/E forward negative
P/S forward 73.83
EV/Sales forward 102.77
Short interest 1.43%
Show more

Is Clene Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Clene Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Clene Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Clene Inc forecast:

Buy
100%

Financial data from Clene Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.34 0.34
48% 48%
100%
- Direct Costs 1.72 1.72
20% 20%
506%
-1.37 -1.37
8% 8%
-403%
- Selling and Administrative Expenses 11 11
4% 4%
3,353%
- Research and Development Expense 19 19
26% 26%
5,494%
-31 -31
18% 18%
-9,250%
- Depreciation and Amortization 1.65 1.65
18% 18%
485%
EBIT (Operating Income) EBIT -33 -33
18% 18%
-9,733%
Net Profit -39 -39
20% 20%
-11,588%

In millions USD.

Don't miss a Thing! We will send you all news about Clene Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clene Inc Stock News

Neutral
GlobeNewsWire
one day ago
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that managem...
Neutral
GlobeNewsWire
9 days ago
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year...
Neutral
GlobeNewsWire
21 days ago
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
More Clene Inc News

Company Profile

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Robert Etherington
Employees 76
Founded 2013
Website www.clene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today